Tang Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Tang Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-800,000	Closed	-$6.24M	–	55
2025 Q4	$6.24M	Hold	800,000	–	–	0.31%	53
2025 Q3	$6.07M	Hold	800,000	–	–	0.23%	89
2025 Q2	$7.17M	Hold	800,000	–	–	0.36%	68
2025 Q1	$6M	Hold	800,000	–	–	0.33%	69
2024 Q4	$6.02M	Hold	800,000	–	–	0.4%	63
2024 Q3	$6.08M	Hold	800,000	–	–	0.43%	64
2024 Q2	$4.94M	Hold	800,000	–	–	0.5%	58
2024 Q1	$4.06M	Hold	800,000	–	–	0.42%	64
2023 Q4	$4.79M	Sell	800,000 -1,000,000	-56%	-$5.79M	0.44%	59
2023 Q3	$12.7M	Sell	1,800,000 -650,000	-27%	-$4.67M	1.8%	16
2023 Q2	$17.2M	Buy	2,450,000 +850,000	+53%	+$6.82M	2.54%	12
2023 Q1	$13.3M	Buy	1,600,000 +150,000	+10%	+$1.44M	1.99%	16
2022 Q4	$16.6M	Buy	1,450,000 +250,000	+21%	+$3.12M	2.42%	13
2022 Q3	$15.1M	Hold	1,200,000	–	–	1.85%	17
2022 Q2	$12.7M	Buy	+1,200,000	New	+$12.4M	1.93%	18
2016 Q3	–	Sell	-430,000	Closed	-$1.22M	–	9
2016 Q2	$1.22M	Hold	430,000	–	–	0.54%	9
2016 Q1	$1.22M	Buy	+430,000	New	+$1.91M	0.55%	11

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Tang Capital Management's BCRX Position: Q1 2026 in Review

Tang Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 800,000 shares — an estimated $6.24M sold.

Tang Capital Management first reported a position in BCRX in Q1 2016 and held it in 17 quarters. The position peaked at $17.2M in Q2 2023. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Tang Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Tang Capital Management sold 800,000 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $6.24M.
Tang Capital Management first reported a position in BioCryst Pharmaceuticals in Q1 2016 and held it in 17 quarters.
Tang Capital Management's BioCryst Pharmaceuticals position peaked at $17.2M in Q2 2023.
302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.